title: High molecular weight hyaluronic acid limits astrocyte activation and scar formation after spinal cord injury.
abstract: A major hurdle for regeneration after spinal cord injury (SCI) is the ability of axons to penetrate and grow through the scar tissue. After SCI, inflammatory cells, astrocytes and meningeal cells all play a role in developing the glial scar. In addition, degradation of native high molecular weight (MW) hyaluronic acid (HA), a component of the extracellular matrix, has been shown to induce activation and proliferation of astrocytes. However, it is not known if the degradation of native HA actually enhances glial scar formation. We hypothesize that the presence of high MW HA (HA with limited degradation) after SCI will decrease glial scarring. Here, we demonstrate that high MW HA decreases cell proliferation and reduces chondroitin sulfate proteoglycan (CSPG) production in cultured neonatal and adult astrocytes. In addition, stiffness-matched high MW HA hydrogels crosslinked to resist degradation were implanted in a rat model of spinal dorsal hemisection injury. The numbers of immune cells (macrophages and microglia) detected at the lesion site in animals with HA hydrogel implants were significantly reduced at acute time points (one, three and ten days post-injury). Lesioned animals with HA implants also exhibited significantly lower CSPG expression at ten days post-injury. At nine weeks post-injury, animals with HA hydrogel implants exhibited a significantly decreased astrocytic response, but did not have significantly altered CSPG expression. Combined, these data suggest that high MW HA, when stabilized against degradation, mitigates astrocyte activation in vitro and in vivo. The presence of HA implants was also associated with a significant decrease in CSPG deposition at ten days after SCI. Therefore, HA-based hydrogel systems hold great potential for minimizing undesired scarring as part of future repair strategies after SCI.
authors.affiliation: Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
authors.forename: Zin Z
authors.initials: ZZ
authors.lastname: Khaing
authors.forename: Brian D
authors.initials: BD
authors.lastname: Milman
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Vanscoy
authors.forename: Stephanie K
authors.initials: SK
authors.lastname: Seidlits
authors.forename: Raymond J
authors.initials: RJ
authors.lastname: Grill
authors.forename: Christine E
authors.initials: CE
authors.lastname: Schmidt
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D001923:Brain Chemistry / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D011508:Chondroitin Sulfate Proteoglycans / Q000096:biosynthesis; D002921:Cicatrix / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D005109:Extracellular Matrix / Q000187:drug effects / Q000378:metabolism; D006820:Hyaluronic Acid / Q000138:chemical synthesis / Q000494:pharmacology*; D020100:Hydrogels / Q000138:chemical synthesis / Q000494:pharmacology; D007150:Immunohistochemistry; D007249:Inflammation / Q000473:pathology; D008262:Macrophage Activation / Q000187:drug effects*; D008970:Molecular Weight; D009457:Neuroglia / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000601:surgery; D013119:Spinal Cord Injuries / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
chemical_list: D011508:Chondroitin Sulfate Proteoglycans; D020100:Hydrogels; D006820:Hyaluronic Acid